Cerus Corporation
CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Sysā¦ read more
Healthcare
Medical Devices
29 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.85
Price+3.26%
$0.09
1Y
Price
Market Cap
$574.346m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1.2%
EBITDA Margin-5.1%
Net Profit Margin-6.1%
Free Cash Flow Margin-1.2%
EBITDA Margin-5.1%
Net Profit Margin-6.1%
Free Cash Flow MarginRevenue
$221.551m
+7.5%
1y CAGR+12.4%
3y CAGR+8.4%
5y CAGREarnings
-$6.783m
+56.6%
1y CAGR+42.0%
3y CAGR+34.6%
5y CAGREPS
-$0.03
+62.5%
1y CAGR+45.8%
3y CAGR+37.5%
5y CAGRBook Value
$70.715m
$205.187m
Assets$134.472m
Liabilities$76.799m
DebtDebt to Assets
37.4%
26.4x
Debt to EBITDAFree Cash Flow
-$1.829m
-121.5%
1y CAGR-1.2%
3y CAGR-19.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company